BTIG Research Reiterates Buy Rating for Merit Medical Systems (NASDAQ:MMSI)

Posted by Brenda Bartman on Aug 11th, 2026

Merit Medical Systems (NASDAQ:MMSI – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $105.00 price objective on the medical instruments supplier’s stock. BTIG Research’s price target suggests a potential upside of 16.99% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Compass Point set a $107.00 target price on Merit Medical Systems in a research report on Monday, April 20th. Raymond James Financial reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 31st. Robert W. Baird set a $98.00 price objective on shares of Merit Medical Systems in a report on Friday, July 31st. Piper Sandler lifted their target price on shares of Merit Medical Systems from $96.00 to $106.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Finally, Weiss Ratings raised shares of Merit Medical Systems from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $100.30.

Read Our Latest Report on Merit Medical Systems

Merit Medical Systems Stock Up 0.8%

Shares of NASDAQ:MMSI opened at $89.75 on Tuesday. Merit Medical Systems has a 52-week low of $59.74 and a 52-week high of $94.75. The company has a market capitalization of $5.36 billion, a PE ratio of 37.09, a price-to-earnings-growth ratio of 2.24 and a beta of 0.48. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20. The company has a fifty day moving average of $72.76 and a 200-day moving average of $71.95.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.23. The company had revenue of $418.84 million for the quarter, compared to the consensus estimate of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.Merit Medical Systems’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, equities analysts predict that Merit Medical Systems will post 3.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Merit Medical Systems

A number of institutional investors have recently modified their holdings of MMSI. Wellington Management Group LLP increased its position in shares of Merit Medical Systems by 377.7% during the third quarter. Wellington Management Group LLP now owns 1,240,509 shares of the medical instruments supplier’s stock worth $103,248,000 after buying an additional 980,823 shares during the period. Norges Bank bought a new stake in Merit Medical Systems during the fourth quarter valued at $75,957,000. Bank of New York Mellon Corp bought a new stake in Merit Medical Systems during the second quarter valued at $28,470,000. Iron Triangle Partners LP acquired a new stake in Merit Medical Systems during the 4th quarter worth about $33,992,000. Finally, Champlain Investment Partners LLC bought a new position in shares of Merit Medical Systems in the 4th quarter worth about $32,359,000. 99.66% of the stock is owned by institutional investors.

About Merit Medical Systems

(Get Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.